Heartflow’s Plaque Analysis tool evaluated over 15,000 patients with up to 16 years of follow-up, demonstrating that extensive coronary plaque volume predicts a fourfold increase in major adverse cardiovascular events, independent of traditional risk factors and stenosis severity. Heartflow enrolled its first patient in the 5,000-patient NAVIGATE-PCI Registry to assess how AI-powered PCI Navigator influences clinical strategy, procedural efficiency and physician confidence by comparing CT-guided intervention planning to angiography alone. In the nearly 3,800-patient DECIDE Registry, centers using AI-driven Plaque Analysis saw significantly higher initiation of lipid-lowering therapy and increased proportion of patients reaching LDL targets below 70 mg/dL after one year, compared to stress-test-guided care. A US payer budget impact analysis showed that AI-guided coronary plaque analysis achieves cost parity with standard care within two years and delivers total population savings of $140 million, as the incremental cost to prevent a MACE event remains below treatment costs.